Complex Immunometabolic Profiling Reveals the Activation of Cellular Immunity and Biliary Lesions in Patients with Severe COVID-19.

COVID-19 GGT IL-6 SARS-CoV-2 T cells acute kidney injury biliary lesion hepatopathy immunity liver disease

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
17 Sep 2020
Historique:
received: 22 07 2020
revised: 04 09 2020
accepted: 10 09 2020
entrez: 22 9 2020
pubmed: 23 9 2020
medline: 23 9 2020
Statut: epublish

Résumé

This study aimed to assess the key laboratory features displayed by coronavirus disease 2019 (COVID-19) inpatients that are associated with mild, moderate, severe, and fatal courses of the disease, and through a longitudinal follow-up, to understand the dynamics of the COVID-19 pathophysiology. All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients admitted to the University Hospital in Motol between March and June 2020 were included in this study. A severe course of COVID-19 was associated with an elevation of proinflammatory markers; an efflux of immature granulocytes into peripheral blood; the activation of CD8 T cells, which infiltrated the lungs; transient liver disease. In particular, the elevation of serum gamma-glutamyl transferase (GGT) and histological signs of cholestasis were highly specific for patients with a severe form of the disease. In contrast, patients with a fatal course of COVID-19 failed to upregulate markers of inflammation, showed discoordination of the immune response, and progressed toward acute kidney failure. COVID-19 is a disease with a multi-organ affinity that is characterized by the activation of innate and cellular adaptive immunity. Biliary lesions with an elevation of GGT and the organ infiltration of interleukin 6 (IL-6)-producing cells are the defining characteristics for patients with the fulminant disease.

Identifiants

pubmed: 32957548
pii: jcm9093000
doi: 10.3390/jcm9093000
pmc: PMC7565504
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agentura Pro Zdravotnický Výzkum České Republiky
ID : NV18-05-00162
Organisme : Agentura Pro Zdravotnický Výzkum České Republiky
ID : NU20-05-00320

Références

Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Immunology. 2020 Jul;160(3):261-268
pubmed: 32460357
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Cell Mol Immunol. 2020 Aug;17(8):878-880
pubmed: 32587367
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529-530
pubmed: 32203680
Cell Res. 2013 Jul;23(7):876-85
pubmed: 23732522
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Liver Int. 2020 Sep;40(9):2095-2103
pubmed: 32239796
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Dermatol. 2017 Jul;44(7):789-797
pubmed: 28295528
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Int J Public Health. 2020 Jun;65(5):533-546
pubmed: 32451563
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Front Mol Biosci. 2020 Jul 03;7:157
pubmed: 32719810
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Allergy. 2020 Jun 4;:
pubmed: 32496587
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Signal Transduct Target Ther. 2020 May 5;5(1):62
pubmed: 32371949
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7
pubmed: 32579880
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
J Infect. 2020 Aug;81(2):205-212
pubmed: 32579986
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
J Clin Immunol. 2020 Oct;40(7):970-973
pubmed: 32594342

Auteurs

Adam Klocperk (A)

Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Marketa Bloomfield (M)

Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.
Department of Pediatrics, 1st Faculty of Medicine, Charles University and Thomayer's Hospital, 140 59 Prague, Czech Republic.

Zuzana Parackova (Z)

Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Irena Zentsova (I)

Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Petra Vrabcova (P)

Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Jan Balko (J)

Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Grigorij Meseznikov (G)

Department of Infectious Diseases, University Hospital in Motol, 150 06 Prague, Czech Republic.

Luis Fernando Casas Mendez (LF)

Department of Pneumology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Alzbeta Grandcourtova (A)

Department of Pneumology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Jan Sipek (J)

Department of Anesthesiology and Intensive Care Medicine, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Martin Tulach (M)

Department of Infectious Diseases, University Hospital in Motol, 150 06 Prague, Czech Republic.

Josef Zamecnik (J)

Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Tomas Vymazal (T)

Department of Anesthesiology and Intensive Care Medicine, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Anna Sediva (A)

Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic.

Classifications MeSH